Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 101–200 of 1,640
Wang, S., Ishima, T., Zhang, J., Qu, Y., Chang, L., Pu, Y., Fujita, Y., Tan, Y., Wang, X., & Hashimoto, K. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01916-z · Cited by 171
Epigenetic signaling in psychiatric disorders: stress and depression
Bagot, R. C., Labonté, B., Peña, C. J., & Nestler, E. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/rbagot · Cited by 171
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“Increases in synaptic spine densities were shown to be preceded by an activation of the mechanistic target of rapamycin (mTOR) [240], as described below.”
BackgroundSelf-citationPu, Y., Tan, Y., Qu, Y., Chang, L., Wang, S., Wei, Y., Wang, X., & Hashimoto, K. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.032 · Cited by 170
Ma, K., Xu, A., Cui, S., Sun, M.-R., Xue, Y.-C., & Wang, J.-H. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.181 · Cited by 168
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“This, in turn, induces activity-dependent plasticity (Buzsaki and Wang, 2012; Duman and Aghajanian, 2012).”
BackgroundResultInfluentialThe Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder
Abdallah, C. G., Averill, L. A., Akiki, T. J., Raza, M., Averill, C. L., Gomaa, H., Adikey, A., & Krystal, J. H. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021701 · Cited by 167
“More recently, accumulating evidence in animal models have shown that repeated, but not acute, treatment with SAAD reverses the depressive-like behavior by increasing BDNF in brain structures known to have stress-related synaptic loss (30; 118).”
BackgroundRoss, D. A., Arbuckle, M. R., Travis, M. J., Dwyer, J. B., van Schalkwyk, G. I., & Ressler, K. J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3325 · Cited by 165
Niciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161
“In slightly more than a decade, the emergence of ketamine’s rapid antidepressant effects has been viewed by some experts in the field as arguably the most important psychiatric discovery in half a century (9).”
BackgroundKarabanov, A., Ziemann, U., Hamada, M., George, M. S., Quartarone, A., Classen, J., Massimini, M., Rothwell, J., & Siebner, H. R. (2015) · Brain Stimulation · doi:10.1016/j.brs.2015.06.017 · Cited by 161
Qin, Z., Shi, D.-D., Li, W., Cheng, D., Zhang, Y.-D., Zhang, S., Tsoi, B., Zhao, J., Wang, Z., & Zhang, Z.-J. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02744-7 · Cited by 162
“Studies have focused on many components of brain including prefrontal cortex (PFC), hippocampus, amygdala, ventral tegmental area (VTA), and nucleus accumbens (NAc), leading to the theories of depression as well as antidepressant response that have been involved in the molecular and cellular signaling mechanisms that…”
BackgroundSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
“One possible exception has to do with another postsynaptic glutamate receptor—AMPA—that can be activated by a putative marked increase in glutamate efflux secondary to ketamine (Duman and Aghajanian, 2012; Li et al, 2011; Maeng et al, 2008).”
BackgroundHippocampal MicroRNA-124 Enhances Chronic Stress Resilience in Mice
Higuchi, F., Uchida, S., Yamagata, H., Abe-Higuchi, N., Hobara, T., Hara, K., Kobayashi, A., Shintaku, T., Itoh, Y., Suzuki, T., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0319-16.2016 · Cited by 158
“Enhancement of GSK3 activity contributed to the reduction in synaptic spine density in response to stress (Collingridge et al., 2010; Duman and Aghajanian, 2012) and postmortem studies have shown increased GSK3 activity in patients with major depressive disorder (Li and Jope, 2010).”
BackgroundInfluentialGlutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 155
“Taken together, the results suggest that mTOR activation via known intracellular second messenger/signal transduction mediators, e.g., MAPK/ERK and PI3K, is necessary for ketamine’s rapid antidepressant-like effects in rodents (Duman and Voleti 2012).”
New targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Kandola, A., Hendrikse, J., Lucassen, P. J., & Yücel, M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00373 · Cited by 155
“…antidepressant treatment had a stronger impact on up-regulating BDNF than either intervention had individually (Russo-Neustadt et al., 2001; Baj et al., 2012) – this is particularly important as BDNF regulation is thought to be crucial to the antidepressant mechanism (Duman and Aghajanian, 2012).”
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0400-x · Cited by 154
Self-citationFang, W., Zhang, J., Hong, L., Huang, W., Dai, X., Ye, Q., & Chen, X. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.013 · Cited by 169
Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder
Murrough, J. W., Abdallah, C. G., Anticevic, A., Collins, K. A., Geha, P., Averill, L. A., Schwartz, J., DeWilde, K. E., Averill, C., Jia‐Wei Yang, G., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23235 · Cited by 153
“However, it is important to highlight that these findings are congruent with the well-described loss of synaptic connectivity in animal models of depression and prolonged stress [Duman and Aghajanian, 2012].”
ResultGABA interneurons mediate the rapid antidepressant-like effects of scopolamine
Wohleb, E. S., Wu, M., Gerhard, D. M., Taylor, S. R., Picciotto, M. R., Alreja, M., & Duman, R. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85033 · Cited by 144
Self-citationChapter 33. Neuroscience of Psychotherapy
Vaughan, S., & Ahmed, M. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg33 · Cited by 151
Li, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 170
GABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
“…the glutamate system and, perhaps most informative, the discovery of antidepressant properties of the NMDA receptor antagonist ketamine has stimulated development of what might become a new generation of fast acting antidepressants (R. S. Duman & Aghajanian, 2012; Krystal, Sanacora, & Duman, 2013).”
BackgroundGABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response
Gunn, B. G., Cunningham, L., Mitchell, S. G., Swinny, J. D., Lambert, J. J., & Belelli, D. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.06.001 · Cited by 149
“…effects by increasing synaptogenesis through complex intracellular signalling cascades, which appear dependent upon the increased synthesis and release of BDNF (Autry et al., 2011; Duman and Aghajanian, 2012; Liu et al., 2012; Dwyer and Duman, 2013; Pilc et al., 2013; Zunszain et al., 2013).”
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
Self-citationTang, J., Xue, W., Xia, B., Ren, L., Tao, W., Chen, C., Zhang, H., Wu, R., Wang, Q., Wu, H., et al. (2015) · Scientific Reports · doi:10.1038/srep13573 · Cited by 149
From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
Corazza, O., Assi, S., & Schifano, F. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12063 · Cited by 146
“Furthermore, KET has been used as a therapeutic tool in a range of remaining conditions, including assisted psychotherapy for people with heroin dependence [12], alcoholism [13,14], resistant depression [15].”
BackgroundOlbrich, S., Tränkner, A., Chittka, T., Hegerl, U., & Schönknecht, P. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.02.010 · Cited by 152
“…experience of negative mood states or transient sadness (Mayberg et al., 1999; Lévesque et al., 2011); a prefrontal dysfunction is thought to account for core symptoms of depression such as anhedonia and cognitive deficits (Pizzagalli et al., 2004; Diener et al., 2012; Duman and Aghajanian, 2012).”
Phoumthipphavong, V., Barthas, F., Hassett, S., & Kwan, A. C. (2016) · eneuro · doi:10.1523/eneuro.0133-15.2016 · Cited by 132
“Namely, fast-acting antidepressants such as ketamine may restore synaptic connections that were lost in stress and mood disorders (Duman and Aghajanian, 2012).”
BackgroundHypothalamus-habenula potentiation encodes chronic stress experience and drives depression onset
Zheng, Z., Guo, C., Li, M., Yang, L., Liu, P., Zhang, X., Liu, Y., Guo, X., Cao, S., Dong, Y., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.01.011 · Cited by 142
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
“This decreases the inhibition of excitatory pyramidal neurons and increases glutamate release and burst [132, 143–145], which continue to activate neurotrophic signaling mechanisms leading to the amelioration of chronic stress-induced synaptic deficits [146].”
BackgroundHao, W., Ma, Q., Wang, L., Yuan, N., Gan, H., He, L., Li, X., Huang, J., & Chen, J. (2024) · Microbiome · doi:10.1186/s40168-024-01756-6 · Cited by 143
“Synaptic pruning is an important link in the formation of correct neural circuits and is crucial for brain development and maintenance of neural homeostasis in depression [8, 9].”
BackgroundMa, Z., Zang, T., Birnbaum, S. G., Wang, Z., Johnson, J. E., Zhang, C.-L., & Parada, L. F. (2017) · Nature Communications · doi:10.1038/s41467-017-01709-8 · Cited by 141
Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. D. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12779-5 · Cited by 134
Lara, D. R., Bisol, L. W., & Munari, L. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 138
“Also, some patients retained their therapeutic response even after stopping ketamine treatment, which may be associated with the strong neuroplastic changes produced by ketamine, as shown in animal studies (Duman and Aghajanian, 2012), but longer and more systematic observations are necessary.”
BackgroundShirayama, Y., Yang, C., Zhang, J.-C., Ren, Q., Yao, W., & Hashimoto, K. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.09.002 · Cited by 137
“Accumulating evidence suggests that the medial prefrontal cortex (mPFC) plays a crucial role in depression (Duman and Aghajanian, 2012; Sun et al., 2013; Duman, 2014; Zhang et al., 2015).”
Molecular biomarkers of depression
Gururajan, A., Clarke, G. A., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.011 · Cited by 151
Lin, S., Huang, L., Luo, Z.-C., Li, X., Jin, S.-Y., Du, Z.-J., Wu, D.-Y., Xiong, W.-C., Huang, L., Luo, Z.-Y., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.02.014 · Cited by 131
Davoudian, P. A., Shao, L.-X., & Kwan, A. C. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00637 · Cited by 129
Wohleb, E. S., & Delpech, J.-C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.013 · Cited by 142
Recent advances in quantitative neuroproteomics
Craft, G. E., Chen, A., & Nairn, A. C. (2013) · Methods · doi:10.1016/j.ymeth.2013.04.008 · Cited by 126
Qu, Y., Yang, C., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-16060-7 · Cited by 127
Ketamine accelerates fear extinction via mTORC1 signaling
Girgenti, M. J., Ghosal, S., LoPresto, D., Taylor, J. R., & Duman, R. S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.026 · Cited by 125
Self-citationAMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123
Principles of inflammasome priming and inhibition: implications for psychiatric disorders
Herman, F. J., & Pasinetti, G. M. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.010 · Cited by 115
Cui, Y., Cao, K., Lin, H., Cui, S., Shen, C., Wen, W., Mo, H., Dong, Z., Bai, S., Yang, L., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00102 · Cited by 123
Wang, J., Chen, H.-S., Li, H.-H., Wang, H.-J., Zou, R.-S., Lu, X.-J., Wang, J., Nie, B.-B., Wu, J.-F., Li, S., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.12.019 · Cited by 122
How could stress lead to major depressive disorder?
Richter-Levin, G., & Xu, L. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.04.001 · Cited by 120
Mao, J., Li, T., Fan, D., Zhou, H., Feng, J., Liu, L., Zhang, C., & Wang, X. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2374-2 · Cited by 120
Regulation of brain-derived neurotrophic factor expression in neurons.
Zheng, F., Zhou, X., Moon, C., & Wang, H. (2012) · PubMed Central · Cited by 160
Regulation of neural circuit formation by protocadherins
Peek, S. L., Mah, K. M., & Weiner, J. A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2572-3 · Cited by 119
“This is consistent with the fact that post-mortem brain tissues from patients diagnosed with mood disorders often show disruptions in dendritic spine density and morphology [197, 198].”
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Orozco-Solis, R., Montellier, E., Aguilar-Arnal, L., Sato, S., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.1176 · Cited by 119
Navarria, A., Wohleb, E. S., Voleti, B., Ota, K. T., Dutheil, S., Lepack, A. E., Dwyer, J. M., Fuchikami, M., Becker, A., Drago, F., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.012 · Cited by 118
“Recent mechanistic studies in rodent models have demonstrated similarities in the downstream cellular actions underlying the rapid antidepressant effects of ketamine and scopolamine (Duman and Aghajanian, 2012; Li et al., 2010, 2011; Voleti et al., 2013).”
BackgroundSelf-citationLiu, S., Xiu, J., Zhu, C., Meng, K., Li, C., Han, R., Du, T., Li, L., Xu, L., Liu, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27044-7 · Cited by 118
Stress and excitatory synapses: From health to disease
Timmermans, W., Xiong, H., Hoogenraad, C. C., & Krugers, H. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.043 · Cited by 127
“Alterations in excitatory synaptic transmission have been implicated in stress-related disorders such as depression (Duman and Aghajanian, 2012).”
Mendez‐David, I., Tritschler, L., Ali, Z. E., Damiens, M.-H., Pallardy, M. J., David, D. J. P., Kerdine‐Römer, S., & Gardier, A. M. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.04.036 · Cited by 122
“Unfortunately, SSRIs need 4 to 6 weeks to produce therapeutic responses and are only moderately effective since approximately 30% of depressed patients are resistant to antidepressant drugs [1,2].”
BackgroundDong, C., Zhang, J.-C., Yao, W., Ren, Q., Ma, M., Yang, C., Chaki, S., & Hashimoto, K. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw089 · Cited by 116
“…protein 95 (PSD-95), and dendritic spine density in brain regions thought to be implicated in ketamine’s antidepressant effects (Autry et al., 2011; Duman and Aghajanian, 2012; Dwyer and Duman, 2013; Lepack et al., 2014; Zhou et al., 2014; Ohgi et al., 2015; Yang et al., 2015a, 2016b; Zhang…”
BackgroundInfluentialOldham, M. A., & Ciraulo, D. A. (2014) · Chronobiology International · doi:10.3109/07420528.2013.833935 · Cited by 115
“Perhaps, the recent demonstration of rapid synaptogenesis in response to ketamine (Duman & Aghajanian, 2012) may fuel further developments in understanding chronotherapeutic mechanisms of action.”
BackgroundSun, Y., Zhang, H., Wu, Z., Yu, X., Yin, Y., Qian, S., Wang, Z., Huang, J., Wang, W., Liu, T., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00371 · Cited by 122
Wang, S., Ishima, T., Qu, Y., Shan, J., Chang, L., Wei, Y., Zhang, J., Pu, Y., Fujita, Y., Tan, Y., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.006 · Cited by 121
The role of neurotrophins in major depressive disorder
Jiang, C., & Salton, S. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0103-8 · Cited by 113
Lally, N., Mullins, P. G., Roberts, M. V., Price, D., Gruber, T., & Haenschel, C. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.07.049 · Cited by 110
“Given the recent surge in research investigating pharmacological manipulations to the glutamatergic system, particularly in the treatment of depression (Duman and Aghajanian, 2012) and schizophrenia (Egerton and Stone, 2012), the task-based event-related approach to (1)H-MRS demonstrated here, could provide a unique e…”
BackgroundZanos, P., Piantadosi, S. C., Wu, H., Pribut, H. J., Dell, M. J., Can, A., Snodgrass, H. R., Zarate, C. A., Schwarcz, R. M., & Gould, T. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225664 · Cited by 121
“…that ketamine’s antidepressant mechanism involves enhanced synaptic glutamate release and activation of postsynaptic AMPA receptors (Li et al., 2010; Duman and Aghajanian, 2012), administration of an AMPA receptor antagonist completely prevented the behavioral effects of 4-Cl-KYN in the FST.…”
BackgroundQiu, A., Shen, M., Buss, C., Chong, Y.-S., Kwek, K., Saw, S.-M., Gluckman, P. D., Wadhwa, P. D., Entringer, S., Styner, M., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx065 · Cited by 114
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
Mkrtchian, A., Evans, J. W., Kraus, C., Yuan, P., Kadriu, B., Nugent, A. C., Roiser, J. P., & Zarate, C. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00878-1 · Cited by 110
New paradigms for treatment‐resistant depression
Zarate, C., Duman, R. S., Liu, G., Sartori, S., Quiroz, J., & Murck, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12223 · Cited by 109
Self-citationZhang, L., Luo, J., Zhang, M., Yao, W., Ma, X., & Yu, S. Y. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001661 · Cited by 110
“…plasticity is the basic underlying mechanism responsible for modifying brain circuitry, and the potential for application of this process in the clinical treatment of depression has received more and more attention (Duman and Aghajanian, 2012; Castrén and Hen, 2013; Russo and Nestler, 2013).”
BackgroundZhang, J., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Ushida, Y., Suganuma, H., et al. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.10.004 · Cited by 116
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15587 · Cited by 134
“…that decreased neuroplasticity and neural atrophy in the prefrontal cortex (PFC) play an essential role in the general pathophysiology of these disorders (Duman & Aghajanian, 2012; Duman et al., 2016; Izquierdo et al., 2006; Pittenger & Duman, 2008; Russo & Nestler, 2013; Qiao et al., 2016).”
BackgroundCognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08609 · Cited by 107
Murrough, J. W., Collins, K. A., Fields, J., DeWilde, K. E., Phillips, M. L., Mathew, S. J., Wong, E., Tang, C. Y., Charney, D. S., & Iosifescu, D. V. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.10 · Cited by 109
Liao, D., Lv, C., Cao, L., Yao, D., Wu, Y. P., Long, M., Liu, N., & Jiang, P. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9268083 · Cited by 117
“Previous studies have reported that dynamic alterations in synaptic and dendritic structure and function play a pivotal role in the development of depression [38, 39].”
BackgroundCarhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., Tanner, M., Bloomfield, M., Williams, T. M., Bolstridge, M., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001405 · Cited by 108
“ketamine) are showing an impressive therapeutic potential (Duman and Aghajanian, 2012).”
BackgroundLateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 106
Murrough, J. W., Wan, L.-B., Iacoviello, B., Collins, K. A., Solon, C., Glicksberg, B., Perez, A. M., Mathew, S. J., Charney, D. S., Iosifescu, D. V., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3255-x · Cited by 108
“Beyond DA, preclinical studies have implicated alterations in neuroplasticity via several mechanisms—including modulation of brain-derived neurotrophic factor (BDNF)—as critical to ketamine's antidepressant action (Autry et al. 2011; Duman and Aghajanian 2012).”
Liu, R.-J., Duman, C., Kato, T., Hare, B., Lopresto, D., Bang, E., Burgdorf, J., Moskal, J., Taylor, J., Aghajanian, G., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.202 · Cited by 105
Self-citationCRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases
Quach, T., Honnorat, J., Kolattukudy, P. E., Khanna, R., & Duchemin, A. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.77 · Cited by 110
CAPON-nNOS coupling can serve as a target for developing new anxiolytics
Zhu, L., Li, T., Luo, C., Jiang, N., Chang, L., Lin, Y., Zhou, H.-H., Chen, C., Zhang, Y., Lü, W., et al. (2014) · Nature Medicine · doi:10.1038/nm.3644 · Cited by 109
Deng, D., Cui, Y., Gan, S., Xie, Z., Cui, S., Cao, K., Wang, S., Shi, G., Yang, L., Bai, S., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154395 · Cited by 114
Liu, Y., Li, M., Fan, M., Song, Y., Yu, H., Zhi, X., Xiao, K., Lai, S., Zhang, J., Jin, X., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.11.025 · Cited by 106
Iñiguez, S. D., Aubry, A., Riggs, L. M., Alipio, J. B., Zanca, R. M., Flores-Ramirez, F. J., Hernandez, M. A., Nieto, S. J., Musheyev, D., & Serrano, P. A. (2016) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.07.001 · Cited by 105
Neuronal and behavioral plasticity: the role of serotonin and BDNF systems tandem
Popova, N. K., & Naumenko, V. S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1572747 · Cited by 105
Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses
Audet, M.-C., & Anisman, H. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00068 · Cited by 104
“The case for BDNF involvement in depression has generally been impressive (Duman and Aghajanian, 2012) but as discussed, the available data do not fully conform to an accounting based solely on BDNF-mediated neurogenesis or neuroplasticity.”
ResultGLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
“stimulating synaptic function and stimulating neuronal signal transmissions [84,85,88,89].”
BackgroundA Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
“A current theory for how the short half-life can translate into enduring benefits is that the drugs engage neurotrophic factors to promote neural plasticity [12,13].”
BackgroundResultOluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
“…neurogenesis in the hippocampus (Boldrini et al., 2012, 2013; Duric et al., 2013; Furtado et al., 2013; Phillips et al., 2015), and preclinical work (Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Bortolotto et al., 2014) supports the hypothesis that depression may disrupt neural…”
BackgroundResultAcute or Chronic? A Stressful Question
Musazzi, L., Tornese, P., Sala, N., & Popoli, M. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.07.002 · Cited by 125
“However, a single administration of ketamine, used at low doses as rapid-acting antidepressant (see above), can restore dendrite arborization compromised by chronic stress in less than 24 h [9,16,24].”
BackgroundLeptin in depression: a potential therapeutic target
Ge, T., Fan, J., Yang, W., Cui, R., & Li, B. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1129-1 · Cited by 118
Shinohara, R., Taniguchi, M., Ehrlich, A. T., Yokogawa, K., Deguchi, Y., Chérasse, Y., Lazarus, M., Urade, Y., Ogawa, A., Kitaoka, S., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.177 · Cited by 110
Tang, J., Yu, W., Chen, S., Gao, Z., & Xiao, B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2504-0 · Cited by 104
Serotonin receptor 4 in the hippocampus modulates mood and anxiety
Karayol, R., Medrihan, L., Warner‐Schmidt, J. L., Fait, B. W., Rao, M. N., Hölzner, E., Greengard, P., Heintz, N., & Schmidt, E. F. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00994-y · Cited by 121
Synaptic Mechanisms Regulating Mood State Transitions in Depression
Parekh, P. K., Johnson, S. B., & Liston, C. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-110920-040422 · Cited by 101
Tornese, P., Sala, N., Bonini, D., Bonifacino, T., La Via, L., Milanese, M., Treccani, G., Seguini, M., Ieraci, A., Mingardi, J., et al. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100160 · Cited by 101
Csabai, D., Wiborg, O., & Czéh, B. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00024 · Cited by 101
“…synaptic level, the stress-induced structural and functional changes of excitatory synapses are the key contributors to the pathophysiology (Popoli et al., 2011; Duman and Aghajanian, 2012; Licznerski and Duman, 2013; Timmermans et al., 2013; Duman, 2014; Thompson et al., 2015; Duman et al., 2016).”
BackgroundLeuner, B., Fredericks, P. J., Nealer, C., & Albin-Brooks, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089912 · Cited by 99
“Moreover, recent evidence suggests that mood disorders like depression may involve dendritic spine loss and other synaptic alterations within the PFC [28].”
BackgroundBouckaert, F., Dols, A., Emsell, L., Winter, F. D., Vansteelandt, K., Claes, L., Sunaert, S. G., Stek, M. L., Sienaert, P. A., & Vandenbulcke, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.86 · Cited by 108
“This hypothesis is in line with the preclinically developed notion that stress is associated with neuronal atrophy and reduced neurogenesis (Duman and Aghajanian, 2012), impaired synaptic plasticity, and dendritic arborization in the hippocampus (Sousa et al, 2000), whereas antidepressants and electroconvulsive stimul…”
BackgroundResultDisorders of memory and plasticity in psychiatric disease
Pittenger, C. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.4/cpittenger · Cited by 92
“This apparently direct connection engenders optimism that other treatments—focused directly on the enhancement of plasticity—may lead to novel avenues for the treatment of depression.(13)”
Background
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.